Brokerages Set Liquidia Co. (NASDAQ:LQDA) PT at $25.38

Shares of Liquidia Co. (NASDAQ:LQDA) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $25.38.

A number of equities research analysts have commented on LQDA shares. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective on the stock. Scotiabank began coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a report on Thursday, January 9th.

Insider Transactions at Liquidia

In other news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 5,226 shares of company stock valued at $59,343 over the last three months. 30.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC acquired a new position in Liquidia during the second quarter worth $27,000. Clear Harbor Asset Management LLC bought a new position in Liquidia in the third quarter valued at approximately $100,000. Signaturefd LLC increased its position in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares during the last quarter. Ballentine Partners LLC bought a new stake in shares of Liquidia during the 3rd quarter worth approximately $110,000. Finally, Whitcomb & Hess Inc. increased its holdings in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Stock Performance

Liquidia stock opened at $11.76 on Friday. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.99. The firm has a market cap of $995.33 million, a P/E ratio of -7.21 and a beta of 0.23. The business’s fifty day moving average is $11.18 and its two-hundred day moving average is $11.02.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).